313 related articles for article (PubMed ID: 19683562)
1. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
[TBL] [Abstract][Full Text] [Related]
2. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
[TBL] [Abstract][Full Text] [Related]
3. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
4. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
5. Reepithelialization of the human cornea is regulated by endogenous opioids.
Zagon IS; Sassani JW; McLaughlin PJ
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
[TBL] [Abstract][Full Text] [Related]
6. Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.
Purushothaman I; Zagon IS; Sassani JW; McLaughlin PJ
Biochem Pharmacol; 2021 Oct; 192():114712. PubMed ID: 34324868
[TBL] [Abstract][Full Text] [Related]
7. Re-epithelialization of the rabbit cornea is regulated by opioid growth factor.
Zagon IS; Sassani JW; McLaughlin PJ
Brain Res; 1998 Aug; 803(1-2):61-8. PubMed ID: 9729280
[TBL] [Abstract][Full Text] [Related]
8. Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.
Diaz D; Sassani JP; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2024; 249():10175. PubMed ID: 38756167
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.
Zagon IS; Sassani JW; Immonen JA; McLaughlin PJ
Clin Exp Ophthalmol; 2014 Mar; 42(2):159-68. PubMed ID: 23777539
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the OGF-OGFr pathway in diabetic bone.
Titunick MB; Lewis GS; Cain JD; Zagon IS; McLaughlin PJ
Connect Tissue Res; 2019 Nov; 60(6):521-529. PubMed ID: 30931654
[No Abstract] [Full Text] [Related]
11. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits.
Zagon IS; Sassani JW; Carroll MA; McLaughlin PJ
Brain Res Bull; 2010 Feb; 81(2-3):248-55. PubMed ID: 19853024
[TBL] [Abstract][Full Text] [Related]
12. The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.
Sassani JW; Mc Laughlin PJ; Zagon IS
J Diabetes Res; 2016; 2016():9703729. PubMed ID: 27703986
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of the OGF-OGFr pathway correlates with elevated serum OGF and ocular surface complications in the diabetic rat.
Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
Exp Biol Med (Maywood); 2020 Sep; 245(15):1414-1421. PubMed ID: 32640891
[TBL] [Abstract][Full Text] [Related]
14. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
15. Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats.
Purushothaman I; Zagon IS; Sassani JW; Mclaughlin PJ
Exp Ther Med; 2021 Jul; 22(1):687. PubMed ID: 33986852
[TBL] [Abstract][Full Text] [Related]
16. Re-epithelialization of the rat cornea is accelerated by blockade of opioid receptors.
Zagon IS; Sassani JW; McLaughlin PJ
Brain Res; 1998 Jul; 798(1-2):254-60. PubMed ID: 9666142
[TBL] [Abstract][Full Text] [Related]
17. Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.
McLaughlin PJ; Sassani JW; Diaz D; Zagon IS
J Diabetes Clin Res; 2023; 5(1):1-10. PubMed ID: 37304310
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats.
Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS
Exp Eye Res; 2009 Nov; 89(5):686-92. PubMed ID: 19576213
[TBL] [Abstract][Full Text] [Related]
19. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
20. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
